BiotechTube

GH001

Phase 2Terminated
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bipolar II Disorder

Conditions

Bipolar II Disorder

Trial Timeline

Apr 6, 2023 → Dec 5, 2024

NCT ID
NCT05839509

About GH001

GH001 is a phase 2 stage product being developed by GH Research for Bipolar II Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT05839509. Target conditions include Bipolar II Disorder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05839509Phase 2Terminated
NCT05804708Phase 2Terminated

Competing Products

20 competing products in Bipolar II Disorder

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
77
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 3
77
FK949E + PlaceboAstellas PharmaPhase 2/3
65
Escitalopram + Bupropion XLLupin LimitedPhase 3
77
OlanzapineEli LillyApproved
85
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
77
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
OlanzapineEli LillyPhase 3
77
LY2979165 + PlaceboEli LillyPhase 1
33
olanzapine + divalproex sodium + placeboEli LillyApproved
85
olanzapine + risperidoneEli LillyApproved
85
LY2979165 + placeboEli LillyPhase 1
33
Topiramate + PlaceboEli LillyApproved
85
olanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyPhase 3
77
Brenipatide + PlaceboEli LillyPhase 2
52

Other Products from GH Research

GH001Phase 2
47
GH001 + PlaceboPhase 2
47
5 Methoxy N,N DimethyltryptaminePhase 1/2
36
5 Methoxy N,N Dimethyltryptamine + PlaceboPhase 1
28
5 Methoxy N,N Dimethyltryptamine + PlaceboPhase 1
28